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Trans-Pacific Partnership Agreement (TPP)
The Trans-Pacific Partnership is a large regional trade 
agreement currently in the final stages of negotiation 
and involves countries around the Pacific Rim, including 
Australia. The agreement is being negotiated under 
conditions of confidentiality, and consequently 
negotiating documents are not made public and 
limited information is available.
Health Impact Assessment (HIA)
During negotiations, an HIA was undertaken on 
provisions in the TPP, to examine the potential impact 
on the health of Australians. HIA is an established way 
of predicting the positive and negative health impacts 
of a policy or proposal to then make recommendations 
to improve that proposal.
The structured steps of the standard HIA process 
(screening, scoping, identification, assessment, 
recommendations and evaluation) were followed, 
while also adapting to this unique context. The HIA 
served as a tool to bring together health advocacy 
organisations in Australia and academics interested 
in outcomes of the TPP. The Public Health Association 
of Australia led this advocacy effort. The HIA assessed 
existing information in the public domain, supported 
by consultation with Australian experts. In the 
absence of official publicly available drafts of the trade 
agreement, the HIA used leaked texts of potential 
provisions and formulated policy scenarios in order to 
conduct the assessment and predict potential impacts. 
The scenarios were based on a select number of high 
priority health policies that could be affected by 
provisions in the TPP and were used to demonstrate the 
potential impact on public health.
The HIA focused on four areas of potential health 
impact:
  the cost of medicines;
  tobacco control policies;
  alcohol control policies; and
  food labelling.
This report provides an overview of the dimensions of 
the TPP relevant to health, the process and findings of 
the HIA - including characterising the potential health 
impacts based on the literature and stakeholder input - 
and recommendations to the Australian Government to 
avoid or mitigate potential harms from the TPP.
We intend for the HIA to inform negotiations and health 
sector advocacy on the TPP.
Key findings
Using the existing evidence base, principally literature 
and population demographics, the HIA team developed 
a causal pathway between each scenario and its 
potential health impacts for the Australian population. 
The HIA found the potential for negative health impacts 
in each of the four areas under investigation. These are 
summarised below.
  Medicine 
The TPP risks increasing the cost of the 
Pharmaceutical Benefits Scheme (PBS), which is 
likely to flow on to the Australian public in terms of 
increased co-payments (out-of-pocket expenses) 
for medicines. This may result in medical non-
adherence for prescription use and prioritising 
health costs over other necessities (food, housing, 
etc.). Vulnerable groups include those from low 
socioeconomic backgrounds, people with chronic 
conditions, younger populations, and Aboriginal 
and Torres Strait Islander peoples. Potential risks to 
health outcomes include declining health status 
in the community, increased hospitalisations and 
increased mortality.
  Tobacco
The TPP provisions pose risks to the ability of 
Government to regulate and restrict tobacco 
advertising. This could potentially lead to increased 
tobacco use and smoking prevalence, resulting 
in increases in tobacco related health harms 
across the community but particularly for existing 
vulnerable groups, such as youth and people with 
low socioeconomic status.
  Alcohol
Some provisions proposed for the TPP have the 
potential to limit regulation of alcohol availability 
and alcohol marketing, and restrict alcohol control 
measures such as pregnancy warning labels. This 
risks increasing alcohol consumption rates and 
abuse, especially amongst young members of the 
community. This may lead to increased alcohol 
related disorders, worsening mental health and 
social disruption in the community.
  Food
There is the potential for TPP provisions to restrict 
the ability of Government to implement new 
food labelling policies, limiting reductions in 
consumption of unhealthy foods. This is associated 
with rates of overweight/obesity and related health 
outcomes.
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Health Impacts
Based on the available evidence, the HIA found the potential for provisions in the TPP to have negative impacts 
on public health. The following matrix maps out the ways the TPP could impact the policy scenarios and their 
subsequent health effects.
Medicine Tobacco Alcohol Food
TPP 
Provisions
  Intellectual property 
chapter
  Healthcare transparency 
annex
  Investment chapter
  Investor-state dispute 
settlement
  Technical barriers to trade 
chapter
  Rules related to 
trademarks in the 
intellectual property 
chapter
  Other protections for 
investors
  Regulatory coherence 
chapter 
  Cross-border services 
chapter
  Investor-state dispute 
settlement
  Technical barriers to trade 
chapter
  Intellectual property 
chapter
  Wine and spirits annex
  Cross-border services 
chapter
  General exceptions
  Investor-state dispute 
settlement
  Technical barriers to trade 
chapter
  Regulatory coherence 
and transparency 
chapters 
  Cross-border services
Policy 
Scenario
   Out-of-pocket expenses 
for patients
  Federal tobacco 
advertising restrictions
  State/Territory advertising 
restrictions
  Federal regulation of 
pregnancy warning labels
  State/Territory regulation 
of alcohol availability and 
alcohol marketing
  Federal regulation of food 
labelling
Health 
Determinants
  Medical non-adherence 
for prescription use
  Prioritising health costs 
over other necessities
  Smoking prevalence   Alcohol consumption 
during pregnancy
  Rate of alcohol 
consumption/abuse
  Consumption of 
unhealthy food
Health 
Outcomes
  Declining health status
  Increased hospitalisations
  Mortality
  Higher use of emergency 
services
  Tobacco-related health 
outcomes:
◊ Cancer
◊ Respiratory diseases
◊ Cardiovascular disease
◊ Reproductive effects
◊ Cataracts
◊ Low bone density
  Declining health status
  Disability
  Death
  Foetal alcohol spectrum 
disorders
  Alcohol-related health 
outcomes:
◊ Cardiovascular disease
◊ Liver disease
◊ Cancer
  Behavioural impacts:
◊ Sexually transmitted 
infections
◊ Child maltreatment
  Psychological impacts
◊ Alcoholism
  Social disruption
◊ Road accidents/Drink 
driving
◊ Pedestrian injury
◊ Violent assault
  Hospitalisation
  Obesity and metabolic 
syndrome
  Obesity-related health 
outcomes:
◊ Cardiovascular disease
◊ Diabetes
◊ Liver disease
Vulnerable 
Populations
  Low socioeconomic 
status
  Aboriginal and Torres 
Strait Islander peoples
  People with chronic 
conditions
  Elderly
  Women
  Culturally and 
linguistically diverse 
groups
  Geographically remote
  Low socioeconomic 
status
  Aboriginal and Torres 
Strait Islander peoples
  Homeless
  People with mental illness
  People in prison
  Drug users
  Adolescents
  Low socioeconomic 
status
  Aboriginal and Torres 
Strait Islander peoples
  Geographically remote
  Adolescents
  Low socioeconomic 
status
  Youth
  Elderly
  Low literacy
  Culturally and 
linguistically diverse 
groups
  Aboriginal and Torres 
Strait Islander peoples
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Recommendations
1 Recommendations to the Department of Foreign Affairs and Trade regarding TPP provisions
1.1 Ensure within the TPP text that public health concerns override economic or trade concerns in any area where these 
priorities may conflict. This means:
  including clear and strong public health exceptions; and
  defining public health as broadly as possible (e.g. not restricting the definition, explicitly or implicitly, to 
emergencies or to particular diseases).
1.2 Do not agree to provisions that potentially increase the cost of medicines for governments or the public. 
1.2.1.  The optimum outcome would be complete exclusion of provisions that impact the cost of medicines from the 
TPP. 
1.2.2.  If such provisions are included, ensure TPP intellectual property provisions do not extend the monopoly rights 
of pharmaceutical companies further, or reduce the flexibility available to governments further, than the 
provisions of the World Trade Organization’s TRIPS Agreement*. 
1.2.3. Actively prevent the practice of ‘evergreening’ § within the TPP.
1.2.4.  Ensure the TPP does not constrain the listing and pricing mechanisms of the Pharmaceutical Benefits Scheme 
(PBS).
1.2.5. Apply a public interest test to anti-competitive practices.
1.3 Ensure the provisions of the TPP do not limit the capacity of governments to introduce and implement priority 
interventions to maintain or improve public health, particularly in the following areas:
  tobacco control;
  reducing harmful use of alcohol; and
  food nutrition labelling.
1.4 Given the harmful effects of tobacco and excessive consumption of alcohol, exclude from the TPP these products, 
policies and laws to regulate them, and any services or investment related to their advertising and promotion, 
distribution, etc.
1.5 Make explicit in the TPP that where there might be any potential conflict between a Party’s obligations under the 
Framework Convention on Tobacco Control (FCTC) and the TPP, the FCTC would have precedence.
1.6 Exclude Investor-state dispute settlement (ISDS) from the TPP as this is a serious threat to public health policies.
1.7 However, if ISDS is included, incorporate effective safeguards in the TPP that prevent investors from making claims 
related to public health and public health service matters. (Noting that the safeguards included in the Korea-Australia 
Free Trade Agreement (KAFTA) are widely acknowledged to be insufficient to prevent claims like the case by Philip 
Morris Asia against Australia over tobacco plain packaging).
1.8 Include wording to ensure that where any disputes arise under the TPP, programs and policies are not assessed for 
their efficacy as only singular intervention points; they must be assessed within the context of a comprehensive suite 
of activities to achieve the health outcome (for example food labelling as one intervention amongst several strategies 
to improve nutrition), or compared to global standards and national strategies.
2 Recommendations to the Australian Government regarding the TPP negotiating process
2.1 Conduct trade negotiations with full public transparency. This means:
  publication of draft texts;
  publication of the Australian Government’s negotiating position on issues of public interest; and
  public release of the final TPP text and examination by both the Joint Standing Committee on Treaties and the 
Senate Committee on Foreign Affairs, Defence and Trade before Cabinet authorises it to be signed. This would 
enable full debate in both Houses of Parliament.
2.2 Ensure public interest stakeholders, including non-governmental health organisations, are informed of issues related 
to health and involved in a structured and organised way with sufficient prior notification for consultation.
2.3 Conduct Health Impact Assessments, with a focus on equity:
  after release of the final TPP text but before it is signed; and
  periodically on new policies or activities resulting from the TPP.
2.4 Apply the precautionary principle† in trade negotiations.
2.5 The Department of Health should undertake regular monitoring of the impacts on health with a particular focus on 
health equity. Ensure monitoring is carried out transparently and publicly reported.
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3 Broader policy recommendations to governments in the areas of medicines, food, alcohol and tobacco
3.1 Keep patient co-payments for the PBS as low as possible to ensure the affordability of medicines.
3.2 The Australian Government should support global efforts to separate the funding of research and development from 
medicine prices.
3.3 Actively support and preserve the PBS.
3.4 Adopt interventions which are part of a comprehensive suite of activities to achieve the health outcome (for example, 
alcohol warning labels as one policy within a suite of alcohol harm reduction interventions).
3.5 Invest research dollars and resources in developing the evidence base for public health interventions.
3.6 Develop clear criteria for protecting and prioritising equity in health policy development; this will help to justify/
support strong, effective and equitable public health policy options.
* The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international agreement administered by the WTO. It 
establishes minimum standards for many forms of intellectual property (IP) regulation, including generous 20-year patent terms for genuine 
pharmaceutical innovation, and flexibilities that allow countries to protect public health interests.
§ Evergreening refers to the way in which the pharmaceutical industry seeks patents for minor modifications to existing pharmaceutical 
products (such as changes to formulations, uses and methods of delivery) in order to extend monopolies and delay generic competition.
† The precautionary principle refers to protective action in the absence of scientific evidence. In situations where there is the potential 
for harm, but there is uncertainty about the magnitude of the impact or causality, then only action to avoid harm or no action should 
be undertaken. See Raffensperger, C. and Tickner, J.A . Protecting public health and the environment: implementing the precautionary 
principle. Washington, D.C: Island Press, 1999.
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Introduction
This report presents the findings of a health impact 
assessment (HIA) conducted in 2014 during the 
negotiations for the Trans-Pacific Partnership 
Agreement (TPP). The HIA assessed the potential impact 
of the TPP on the health of Australians. This chapter 
introduces the TPP and provides an overview of the 
main health-related concerns. It outlines the process for 
the HIA and discusses the limitations of the study.
The main body of the report summarises the findings of 
the HIA in four areas of potential impact:
  The cost of medicines;
  Tobacco control policies;
  Alcohol control policies; and
  Food labelling.
The report also includes a set of recommendations to 
the Australian Government developed by the advocacy 
organisations.
Trade and Health
Trade agreements serve to regulate the flow of 
goods, services and technologies between countries. 
Traditionally, a free trade agreement (FTA) is an 
agreement between two or more countries which aims 
to remove barriers to trade such as tariffs or import 
quotas to member countries. Increasingly FTAs have 
shifted to encompass not just the regulations related 
to the exchange of goods and services but also to rules 
regarding intellectual property (IP), investment and 
many other issues. As these rules have expanded, so too 
has their potential to impact upon domestic policies 
that affect public health.
In this report we define health broadly as according to 
the definition of the World Health Organization (WHO):
“Health is a state of complete physical, mental and 
social well-being and not merely the absence of 
disease or infirmity.”1
We understand health to be determined by a complex 
interaction between the social and economic 
environment, the physical environment, and the 
person’s individual characteristics and behaviours. The 
social determinants of health are the conditions in 
which people are born, grow, live, work and age. These 
circumstances are shaped by the distribution of money, 
power and resources at global, national and local levels.
The Trans-Pacific Partnership Agreement
The TPP is a large regional trade agreement in the final 
stages of negotiation in 2015. Participating countries 
include Australia, Brunei, Canada, Chile, Japan, Malaysia, 
Mexico, New Zealand, Peru, Singapore, Vietnam and the 
United States (US).
If concluded in 2015, the TPP will become the largest 
regional trade agreement to date. According to the 
Department of Foreign Affairs and Trade (DFAT)2 and 
based on 2013 figures, the TPP covers 37.5% of world 
gross domestic product (GDP), 11.2% of the world’s 
population and 25% of global trade.
Negotiations for the TPP began in March 2010. Almost 
five years later, much of the legal text of the agreement 
has been settled, but core areas of disagreement 
remain amongst the negotiating countries. One of 
the reasons for delays in concluding the negotiations 
hinges on disagreement over agricultural market access 
issues. Another contributing factor is concerns that 
have been raised about the potential impact of the TPP 
on domestic policy making in areas such as health and 
the environment. 
While the TPP includes traditional trade issues such as 
the removal of tariffs (import taxes) and other barriers 
to the flow of goods and services across the border of 
countries, it also aims to extend into areas that have 
traditionally been matters for each nation to determine 
through democratic policy making processes. 
National and international health and development 
organisations have raised concerns about the potential 
health and human rights impacts of the TPP. Some of 
these include reduced access to affordable medicines, 
reduced effectiveness of tobacco and alcohol policies, 
reduced food security and poorer nutrition, increased 
costs of providing health services, adverse impacts 
on the physical environment and increased risk of 
exposure to environmental hazards.
Despite these potentially negative and wide ranging 
consequences for public health, the negotiations for the 
TPP are conducted under conditions of confidentiality. 
The public (and public health professionals) have not 
had access to draft texts and only limited information 
about the negotiations is available. In contrast, US-
based industry organisations have had access to the 
text and much greater influence over the negotiations.
The Australian Government has stated that it will not 
accept any provisions in the TPP that will negatively 
affect health in Australia. For example, the TPP web 
page of DFAT3 states:
“The Government has made it clear that it will not 
accept any TPP outcome which undermines the 
integrity of the [Pharmaceutical Benefits Scheme]. 
Nor will the Government permit any outcome which 
compromises Australian health policy more generally.”
However, leaked negotiating texts show that many of 
the provisions being discussed in the TPP negotiations 
are potentially harmful to health, and in the context of 
trade negotiations, trade-offs can be made between 
different issues as part of the negotiating process.
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Overview of Health Concerns
The draft text of the TPP is not publicly available, nor is there a publicly available list of chapters and annexes 
(which are likely to be fluid during the negotiations in any case). However, DFAT provides a list of “issues covered by 
the TPP”.4 Table 1 presents an outline of the parts of the TPP chapter or negotiating area that have been identified 
as potential health concerns by stakeholders.
Chapter/ 
negotiating area Likely contents Possible health implications
Intellectual 
property (IP)*
Includes a set of obligations for countries to implement 
in their domestic laws to protect intellectual property, 
including patents, trademarks and copyright.
  Longer and broader monopolies on medicines and 
other health technologies.
  Protection of other types of IP such as trademarks 
(e.g. on cigarette packaging).
Transparency Transparency provisions generally involve requirements to 
provide notice and publish information about policy and 
administrative changes, and to provide review and appeal 
mechanisms. An annex* to the Transparency Chapter 
includes a specific set of provisions for pharmaceutical 
pricing and reimbursement schemes like Australia’s 
Pharmaceutical Benefits Scheme (PBS).
  Corporations may be better equipped to oppose 
proposed public health legislation/regulation.
  The ‘healthcare transparency annex’ may preclude 
use of effective pricing mechanisms and give 
companies more leverage in PBS listing decisions.
Investment* Protections for investors (i.e. corporations from one TPP 
country that invest in another TPP country). Investments 
can include intangibles like intellectual property as well as 
more tangible financial investments.
Protections include access to an ‘investor-state dispute 
settlement’ (ISDS) mechanism that allows corporations to 
sue governments for monetary compensation outside of 
domestic court systems.
  ISDS may deter countries from introducing and 
implementing new healthcare and public health 
policies if they have concerns about litigation 
(which is very expensive, particularly for smaller 
countries and developing countries).
  There are precedents of ISDS cases over public 
health issues including tobacco control and patents.
Technical barriers to 
trade (TBT)
Provisions in TBT chapters are intended to remove or 
streamline ‘barriers to trade’ such as technical regulations 
and standards that are applied to imported products (for 
example, labelling requirements). The TBT chapter has a 
number of annexes for different products, including one for 
wine and distilled spirits.
  TBT provisions may facilitate challenges by 
corporations (or by countries on behalf of 
corporations) to regulations that have a public 
health purpose.
  Provisions in the TBT wine and spirits annex 
may limit the ability of countries to stipulate 
requirements for health warnings.
Sanitary and 
phytosanitary 
measures (SPS)
SPS chapters in trade agreements contain provisions 
related to imports of animal and plant related goods – such 
as quarantine standards. The US agricultural industry is 
seeking harmonisation of standards (which may mean 
lowering of standards in other countries including 
Australia).
  SPS provisions may cause downward pressure on 
food safety and nutritional standards.
Trade in goods 
(market access)
Market access provisions aim to lower direct barriers to 
entry of goods and services, such as tariffs (import taxes) 
and quotas.
  Lowering barriers to entry of unhealthy products 
(e.g. tobacco, alcohol, processed foods) may 
facilitate increased consumption.
Cross-border trade 
in services
These chapters in trade agreements usually include 
provisions related to services, including distribution, 
marketing, licensing, etc. The aim is to reduce barriers to 
trade in services and ensure that services provided by 
companies in other countries can compete on an equal 
footing with domestic services.
  Unless all current and future health services are 
explicitly excluded, they are likely to be covered by 
these commitments.
  This may reduce the capacity of government 
control over regulation of health services.
Competition 
and state owned 
enterprises
According to news commentary, this highly controversial 
chapter includes provisions to ensure that foreign 
corporations can compete on equal terms with 
organisations owned by the state.
  Unless all current and future health services are 
explicitly excluded, they are likely to be covered by 
these commitments.
  This may reduce the capacity of government 
control over regulation of health services.
Government 
procurement
These types of chapters place obligations on government 
purchasing of goods and services (to ensure that local/
domestic companies are not advantaged over foreign 
companies).
  Could place limitations on government purchasing 
of locally produced products and services; may 
have implications for provision of food services for 
example.
Regulatory 
coherence*
Aims to streamline regulation across TPP countries, 
specifies how governments go about policy making; 
includes consultation and coordination mechanisms.
  Could provide a greater role for industry in the 
policy making process; a particular concern in 
areas where there are conflicts of interest between 
corporate and public health goals (e.g. tobacco and 
alcohol regulation).
*Proposals or composite drafts of these chapters/annexes have been leaked and are available in the public domain. It is important to note that many of these 
proposals and drafts are likely to have been superseded, and that for many chapters there have been no leaks.
Table 1 TPP chapter or negotiating area
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HIA Process
HIA is a combination of procedures, methods and tools 
by which a policy, program or project may be assessed 
and judged for its potential effects on the health of 
the population and the distribution of these impacts 
within the population.5 HIAs, which may be undertaken 
at local, regional, national or international levels, are 
intended to inform decision making. Thus, HIA reports 
identify potential impacts on health and also make 
recommendations about ways in which predicted 
desirable health impacts could be maintained or 
enhanced and how undesirable health impacts could 
be avoided or minimised.6 HIA has been identified as 
one of a limited number of methods that are available 
to address the social and environmental determinants 
of health prior to implementation of proposed policies, 
plans or projects to maximise future health benefits 
and to minimise risks to health.7-9 The methods and 
tools used within HIA vary but there are standard steps 
involved:
  screening;
  scoping;
  identification;
  assessment; 
  decision making; and 
  recommendations.
Work on the TPP HIA began in December 2013 and was 
completed in February 2015.
A small working group comprised mainly of experts on 
HIA led the HIA process. A technical committee made 
up of 11 public health experts supported the working 
group and provided feedback on the research, scope, 
analysis, findings and recommendations. An advocacy 
group made up of 11 civil society organisations 
supported the HIA process and utilised HIA findings to 
inform their work in the area. Members of both groups 
provided advice and access to evidence to inform the 
HIA.
For the HIA we applied a range of methods including: 
  reviewing literature for evidence about the 
potential impacts of trade agreements on health; 
  accessing national data; 
  consulting with experts; and 
  carrying out an assessment workshop with 35 
participants. 
The assessment workshop was crucial to the process as 
a range of stakeholders from advocacy organisations 
were able to discuss and agree on the evidence-
informed impact pathways for each scoped area 
and then use this analysis to identify some initial 
recommendations.
In the absence of public documents, the HIA 
used leaked texts of potential provisions and 
formulated policy scenarios in order to conduct the 
assessment and predict potential impacts. 
This HIA is intended for use by health advocacy 
organisations interested in the TPP negotiations. Many 
organisations have been involved in a wide range 
of efforts to advocate for more transparency in the 
negotiations process, and better protection of public 
health in trade provisions. This report may also be used 
by trade negotiators to better understand some of the 
implications for health of provisions in the TPP. 
Figure 1 HIA Steps
Limitations of the study
HIAs can be carried out at different depths ranging from 
desktop assessments using already available evidence 
to comprehensive assessment that involves collecting 
and analysing data from multiple sources requiring 
significant time and resources. Our analysis is not 
comprehensive. This is an intermediate level HIA carried 
out with time and resource restrictions. 
The project was done almost entirely through people 
volunteering their time, with the exception of funding 
from the Centre for Health Equity Training, Research 
and Evaluation for a research associate to support the 
process, and support from the Public Health Association 
Australia to host the assessment workshop. Bearing this 
in mind we focused on a limited number of scenarios 
and areas of impact. The actual impacts of the TPP will 
be much broader than those scoped in this report (for 
example there are important potential environmental 
and social impacts which were beyond the scope of 
Screening
Determine whether HIA is appropriate and 
required
01
Scoping
Set out the parameters of the HIA
Identification
Develop a community/population profile 
and collect information to identify 
potential impacts
Assessment
Synthesise and critically assess the 
information in order to prioritise health 
impacts
04
Decision making & recommendations
Make decisions to reach a set of final 
recommendations for acting on the HIA’s 
findings
Evaluation & follow-up
Evaluate the processes involved in the 
HIA and its impact, and follow up the HIA 
through monitoring and a health impact 
management plan
06
02
03
05
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Step What we did Outcomes
Screening   The HIA team convened a screening meeting of 
the Technical Advisory Group (n=11) to develop 
an overview of the proposal, the potential health 
implications and opportunities to influence the 
TPP negotiations and outcomes.
  Decision made to conduct a rapid advocacy HIA to inform 
and influence TPP process and provide evidence to 
support and inform advocacy groups.
Scoping   A scoping meeting was held with the Technical 
Advisory Group to determine the focus of the 
assessment and plan the process. This was 
followed by an Advocacy Advisory Group (11 
advocacy organisations) meeting to discuss 
involvement and role of advocacy groups.
  Focus areas: cost of medicines; and the ability of 
Government to regulate tobacco, food and alcohol.
  Geographic focus: Australia.
Policy Brief 
(review of the 
evidence)
  The policy brief – separate to the HIA but which 
informed the predictions and recommendations 
– compiled existing evidence from the literature 
about the potential impacts of the TPP on 
various public health policies.
  A 20 page policy brief and press release to inform the 
negotiators meeting occurring in February 2014.
Scenario 
development
Policy scenarios were developed in consultation with 
policy experts and based on the following criteria:
  That the policy scenario is either a current 
priority or likely to become a priority for 
advocacy groups. 
  The scenario includes a globally recognised 
public health intervention with a strong 
evidence base.
  Based on previous trade agreements, TPP 
provisions will likely impact the policy scenario.
Policy scenarios:
  Change in regulation of pregnancy alcohol warning 
labels.
  Change in the regulation of alcohol availability.
  Change in the regulation of alcohol marketing.
  Change in the regulation of food labelling.
  Change in the cost of medicines.
  Change in Federal tobacco advertising policies.
  Change in State/Territory tobacco marketing policies.
Data collection   Secondary data was compiled to identify 
how the scenarios may impact on health. This 
included:
•	 Baseline	profiling	of	existing	conditions	and	
population health using available data for 
Australian context. A literature review focusing 
on reviews of evidence and literature identified 
and recommended by Technical and Advocacy 
Advisory Group members and additional 
subject experts interviewed for the scenario 
development.
•	 Policy	analysis	of	relevant	Australian	and	
international policies.
  Preliminary impact pathways, assessment matrices and 
evidence summaries developed.
Impact analysis   A workshop was held with members of Technical 
and Advocacy Advisory Group members and 
other relevant stakeholders to discuss and 
validate the findings of the assessment and 
develop recommendations for policy options 
and further advocacy.
  Draft recommendations.
  Validation of impact pathways and assessment matrices.
  Impact characterisation.
Report on 
health impacts 
and policy 
options
  A draft report was compiled by the HIA team and 
circulated to the technical and advisory group 
for comment before finalisation.
  HIA report detailing the methods, findings and 
recommendations of the HIA. The report will be 
translated into various communication documents and 
disseminated to advocacy partners, TPP negotiators, the 
media and the public.
Monitoring and 
evaluation
  The HIA team will work with advocacy partners 
to develop a plan to monitor the TPP, evaluate 
the impacts of the HIA and conduct a process 
evaluation.
this particular HIA). There are many other important 
independent factors that will contribute to how the TPP 
impacts on health which were not feasible to assess. 
Given that the scope and depth of our assessment were 
limited there are two further important caveats to bear 
in mind: the TPP proposals on which the HIA is based 
are unlikely to fully represent the final text; and future 
policies that are likely to be impacted on by the TPP are 
also unknown. We recommend that a comprehensive 
HIA be carried out on the final text to identify the full 
range of potential impacts on health.
Table 2 HIA process
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This section describes the dimensions of the TPP relevant to health and the pathway in which these provisions can 
lead to changes in health in the four scoped areas:
  the cost of medicines;
  tobacco control policies;
  alcohol control policies; and
  food labelling.
Unlike most HIAs, the TPP HIA was faced with the difficulty of arriving at impact predictions without the use of a 
publicly available proposal to assess.
In the absence of public documents and final provisions, the HIA used leaked texts of potential provisions and 
formulated policy scenarios in order to conduct the assessment and predict possible impacts. The scenarios are 
high priority public health policies, which could be impacted by provisions in the TPP. 
The scenarios were developed with policy experts in each area based on the following criteria:
  the policy scenario is either a current priority or likely to become a priority for advocacy groups; 
  the scenario includes a globally recognised public health intervention with a strong evidence base;
  based on previous trade agreements, the policy scenario will likely be impacted by TPP provisions.
The scenarios are used to demonstrate ways in which the TPP could potentially affect public policies, and the 
subsequent health effects from these impacts. There are many other potential ways that the TPP could impact 
public policy but due to the secretive nature of the negotiating process, there was no way to determine the scope 
of all potential policies that could be affected.
Each section includes:
   a description of current health conditions in Australia;
  the current status of the policy scenario and how changes to the policy scenario impact health;
  the characterisation of potential health impacts resulting from the TPP; and 
  recommendations to mitigate any potential harms. 
Each section also includes a description of specific equity considerations for each pathway, such as how potential 
changes may have greater impacts on vulnerable populations.
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TPP provisions have the potential to increase the 
cost of medicines, which would in turn mean greater 
expenses for the Pharmaceutical Benefits Scheme (PBS). 
In the past, the PBS has increased patient co-payments 
in order to accommodate rising costs.10 This section 
assesses the ways in which the TPP may lead to an 
increase in out-of-pocket medicine costs for Australian 
patients§ and how this impacts health.
Current status of prescription use and costs in 
Australia 
In 2013, pharmaceuticals accounted for 13.1% of 
total health expenditure in Australia.11, 12 In 2010, 
Australians spent an average of $1,075 on out-of-pocket 
expenses.13 On average over one third (38.2%) of out-of-
pocket medical expenses are for medicines.11 In 2012, 
16% of Australians experienced a cost-related access 
problem (did not fill or skipped a prescription, did not 
visit a doctor, or did not receive recommended care).13
The key mechanism for reducing out-of-pocket 
pharmaceutical expenses in Australia is the PBS. 
The PBS provides public subsidies for prescribed 
medicines; decisions about which medicines are 
subsidised are made on the grounds of comparative 
safety and efficacy, as well as cost-effectiveness. Like 
other pharmaceutical coverage and reimbursement 
programs, the PBS is important not only for supporting 
affordable access to medicines, but also for containing 
health care costs and ensuring value for money. The 
manner in which it operates – the way decisions are 
How the TPP could affect the Cost of Medicines
Figure 2 Medicines pathway
made about which medicines to subsidise and how 
much to pay – has profound consequences both for the 
health of individuals and for the healthcare expenditure 
of Australian Governments.
Although the PBS offers concessions for low-income 
patients, there still exist financial barriers to prescription 
use. In particular out-of-pocket expenses (such as 
patient co-payments) can be a barrier.14, 15 In a 2007 
survey of patient behaviour, roughly 21% reported 
buying an over-the-counter medicine instead of a 
prescription, 48% asked their doctor for a cheaper 
medication, 18% used a medicine already at home 
rather than buy a new prescription, and 6% used a 
medication belonging to someone else.16 All of these 
behaviours were significantly more likely to occur in 
patients who reported moderate to extreme financial 
burden from the cost of their prescriptions.16 In a survey 
of residents in the Hunter Valley from 2011, 28% said 
that an increase in the cost of co-payments would 
change their use of medications.17
How a change in the cost of medicines impacts 
health
TPP provisions that potentially expand and extend 
patent monopolies, keeping drug prices high for 
longer periods and delaying the availability of generic 
medicines, are likely to increase the cost of medicines 
and result in greater expenses for the PBS. The PBS has 
increased patient co-payments in the past in order 
to accommodate rising costs.10 Such increases in the 
   Out-of-pocket expenses for patients
Policy
Scenario
  Medical non-adherence for prescription use
  Prioritising health costs over other necessities
Health 
Determinants
  Declining health status
  Increased hospitalisations
  Mortality
  Higher use of emergency services
Health 
Outcomes
  Intellectual property chapter
  Healthcare transparency annex
  Investment chapter
TPP 
Provisions
  Low socioeconomic 
status
  Aboriginal and Torres 
Strait Islander peoples
  People with chronic 
conditions
  Elderly
  Women
  Culturally and 
linguistically diverse 
groups
  Geographically remote
Vulnerable 
populations
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§ It is important to note that proposed provisions for the TPP will have a more profound effect on access to medicines, and therefore health, in the developing 
countries in the TPP. Reduced access to medicines in developing countries in the region could also have implications for Australians, through failure to control 
infectious diseases and through the potential impact on the foreign aid budget. These issues are beyond the scope of the HIA.
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cost of medicines have been shown to have negative 
impacts on health. Affordability of medicines is a key 
reason for prescription non-adherence.18 A systematic 
review of evidence from 1990 to 201119 found that co-
payments:
  decrease prescription use; 
  can impact patient medicine use compliance; and 
  can adversely impact disadvantaged populations.
In 2005, the PBS raised co-payments by 21%. A study of 
this increase found a decrease in dispensing of between 
3% and 11% for 12 of the 17 medicines that were 
monitored.20 There were significantly higher declines 
in prescription use for concessional patients than 
general patients. The study also found that the price 
increase led to a decline in dispensing of proton pump 
inhibitors (drugs commonly used to treat gastric acid 
conditions) across all geographical areas, indicating 
that the price change impacted not only disadvantaged 
populations but also all Australians.20 In the US, patients 
with reported medication-cost problems, in addition 
to underuse, also reported spending less on necessities 
such as food, housing and energy costs.21
The burden of higher cost sharing not only leads to 
financial strain on patients, but also can have significant 
health impacts. In the US patients with higher cost-
sharing for prescriptions had poorer adherence to 
drug therapy, poorer health outcomes, and higher 
use of emergency services.22, 23 Higher co-payments 
discourage medicine use and may lead to downstream 
costs such as increased hospitalisations.24 In the US, 
over 30% of chronically ill patients who reported 
underusing medications due to costs reported a 
significant decline in health status over a two year 
study.25 Although on the face of it reduced medicine 
use may appear to save money, it leads to significant 
longer-term costs associated with more complicated 
and prolonged illness.22, 23
Equity consideration: How the cost of medicines 
impacts certain populations
Higher prescription costs for patients lead to a greater 
reduction in medicine use in vulnerable populations 
than for the general population.19 Women, elderly 
adults, cultural and linguistic minorities, low-income 
populations, and people with chronic disease report 
the most difficulty with financial barriers to prescription 
use.26, 27 In one study, 20% of respondents with an 
annual out-of-pocket expense of approximately $630 
or more reported underuse of medications due to 
costs.27 In Australia, underuse was higher in younger 
populations (18-64 years old) compared with older 
populations, and Aboriginal and Torres Strait Islander 
patients were three times more likely to report 
underuse than non-Aboriginal and Torres Strait Islander 
patients.27 
Both geographically remote and low-income 
populations have the lowest use of prescription 
medications.28 This is especially relevant as many of 
these sub-populations, particularly Aboriginal and 
Torres Strait Islander peoples, already have the poorest 
health.29-31 People of most disadvantage are more 
likely to die from heart, stroke and vascular diseases 
than people of the most advantage.32 Statins – a type 
of medication used to treat heart disease – are used 
the least in areas of economic disadvantage despite 
this group having the highest rates of cardiovascular 
disease.33 Aboriginal and Torres Strait Islander peoples 
are more likely to have a chronic condition (twice 
as likely as non-Aboriginal and Torres Strait Islander 
peoples) with 36% over age 15 having a disability, and 
are more likely to die from chronic disease.34 People 
with chronic disease are also more vulnerable to price 
fluctuations. In a study of the financial burden of 
managing a chronic illness, 45% were unable to pay 
at least one medical or living expense in the past year. 
People who were economically disadvantaged spent 
more to manage their illness than those who were not 
experiencing economic hardship.35  Thus, cost burden 
falls most heavily on those with multiple chronic 
conditions and those least able to bear it - a group who 
are vulnerable both in terms of health and income.
Provisions proposed for the TPP that have 
implications for the cost of medicines
There are many different parts of the TPP that may 
have implications for the cost of medicines. Below we 
explore the implications of the IP chapter, an annex to 
the transparency chapter, and the investment chapter 
of the TPP. However, it is important to note that other 
parts of the TPP text, such as the regulatory coherence 
chapter, the transparency chapter and the technical 
barriers to trade chapter, may also contain provisions, 
including accountability and enforcement mechanisms 
that could also affect the cost of medicines.
Intellectual property chapter
Successive leaked draft negotiating documents36, 37 
show the US is seeking the inclusion of provisions that 
would, via a range of different mechanisms, expand 
and extend patent monopolies, keep drug prices high 
for longer periods and delay the availability of generic 
medicines.38-40
The most recent draft of the IP chapter of the TPP37 
indicates that some of the initial demands of the US 
have been dropped or watered down. The removal or 
mitigation of some of the worst elements of earlier US 
proposals is likely to be due to opposition by the other 
countries and the efforts of civil society stakeholders. 
However, there is still much to be concerned about. 
Some of the provisions in the 2014 draft would 
further entrench existing arrangements in Australia 
that already contribute to high medicine prices. For 
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example, the US is seeking to prevent countries from 
refusing to grant patents for minor variations to existing 
products even when there is no evidence of additional 
benefit. This provision would encourage ‘evergreening’ 
of patents - a strategy patent holders use to extend 
their monopolies by gaining additional patents, thus 
preventing competition from cheaper generic versions 
for longer periods. The 2014 text37 appears to indicate 
Australia’s agreement with this proposal.
Another provision proposed by the US allows for 
patent term extensions to compensate for delays in 
issuing patents or in obtaining marketing approval. In 
Australia, drug companies can already get patent term 
extensions of up to five years for new pharmaceutical 
products. Earlier drafts indicated the US was pursuing 
patent term extensions for a wider range of patents, 
including for new methods of making or using 
pharmaceutical products.38 In the most recent draft, the 
scope has narrowed to new pharmaceutical products.37 
However, this would still lock in arrangements in 
Australia that keep drug prices high. The 2013 Review 
of Pharmaceutical Patents found that patent term 
extensions already cost Australian taxpayers in excess of 
$200 million dollars per year.41
The US is also seeking to lengthen the period during 
which generic manufacturers cannot use clinical 
trial data produced by the manufacturer to obtain 
marketing approval for a generic version of the drug 
(this is known as ‘data protection’ or ‘data exclusivity’). 
Under the Australia-US Free Trade Agreement, Australia 
must already provide at least five years of protection for 
a new pharmaceutical product. But the US is seeking 
at least three additional years of data protection for 
new uses of existing drugs42 and up to twelve years 
for biologic products (drugs and other products such 
as vaccines that are derived from cells or tissues).43 
A submission to DFAT by Gleeson, Lopert and Moir44 
shows that extending monopolies on biologic drugs 
through longer periods of data protection is also likely 
to cost the PBS in the order of hundreds of millions of 
dollars each year.
There has been considerable opposition to the US 
proposals by the other countries, and the current state 
of the negotiations on IP is unclear. The Australian 
Government’s stated position is that it will not accept 
anything in the TPP that would adversely affect the 
PBS.45
Healthcare transparency annex
A draft US proposal for a TPP Annex on ‘Transparency 
and Procedural Fairness for Healthcare Technologies’, 
leaked in 2011,46 included provisions that would 
constrain the ability of the PBS to contain medicine 
prices and ensure value for money. These provisions 
would:38
  Preclude therapeutic reference pricing, an 
important mechanism for ensuring that the prices 
paid for medicines reflect their clinical benefit 
(therapeutic reference pricing involves linking the 
price of a new medicine to other medicines that are 
already available for the same condition);
  Introduce onerous obligations for transparency and 
information disclosure (facilitating pharmaceutical 
industry influence over decisions about which 
drugs to list and how much to pay for them);
  Extend opportunities for manufacturers of 
pharmaceuticals and medical devices to influence 
decision making regarding listing, pricing and 
reimbursement;
  Include review/appeals processes which would 
enable the overturning of listing and pricing 
decisions made by government agencies and 
committees including health and economics 
experts;
  Legalise direct-to-consumer advertising via the 
internet (which is currently prohibited in Australia 
due to concerns about the effect it can have 
on rational prescribing such as encouraging 
overuse of medicines that may be inappropriate 
or unnecessary or are not the best option for the 
particular condition); and
  Establish mechanisms for ongoing input by US 
trade officials into decision making about the PBS.
This proposal was reportedly rejected by the other 
countries.47 In December 2013, leaked negotiating 
documents suggested that Australia and Japan had 
worked with the US on a revised proposal.48 Recent 
commentary49, 50 suggests that the recent revision may 
be more similar to the provisions in the Australia-US 
Free Trade Agreement than the original US proposal, 
which would mean less extensive changes to Australia’s 
PBS than the original US proposal. However, there 
are still considerable risks involved in negotiating 
provisions that will affect the PBS.
Investment chapter
A draft of the investment chapter leaked in 201251 
indicated that an ISDS mechanism was being 
negotiated for the TPP. This mechanism enables foreign 
corporations to sue governments in international 
tribunals when they perceive that a change in 
government policy or law reduces the value of their 
investment. The current Coalition Government has 
adopted a policy of negotiating ISDS mechanisms on 
a case-by-case basis in bilateral and regional trade 
agreements, and is open to its inclusion in the TPP. 
This reverses the position of the previous Government, 
which was opposed to the inclusion of ISDS in trade 
agreements based on the recommendations of the 
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Productivity Commission.
An ISDS mechanism in the TPP may allow 
pharmaceutical companies based in the US or other 
TPP countries to sue the Australian government over 
pharmaceutical policies and laws. For example, Eli Lilly 
and Company, a US-based pharmaceutical company, is 
suing the Government of Canada for CAD $500 million 
over Canadian court decisions to revoke patents on 
two drugs.52 Even when such cases are unsuccessful, 
the threat of litigation may deter governments from 
implementing policies and laws.
Impact prediction
There are several provisions in the TPP that may lead to 
an increase in the costs of medicines, and subsequently 
a higher out-of-pocket expense for patients. Given 
the public health evidence, discussed above, that 
increases in patient co-payments lead to lower rates 
of prescription use, it is likely that any provisions in 
the TPP that raise the cost of medicines will have a 
negative impact on health. This is particularly relevant 
for vulnerable populations such as low-income patients 
and people with chronic conditions.
* The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international agreement administered by the WTO. It 
establishes minimum standards for many forms of intellectual property (IP) regulation, including generous 20-year patent terms for genuine 
pharmaceutical innovation, and flexibilities that allow countries to protect public health interests.
§ Evergreening refers to the way in which the pharmaceutical industry seeks patents for minor modifications to existing pharmaceutical 
products (such as changes to formulations, uses and methods of delivery) in order to extend monopolies and delay generic competition.
Recommendations
In order to avoid negative impacts to health associated 
with a rise in the cost of medicines, we recommend the 
following:
1. Do not agree to provisions that potentially increase 
the cost of medicines for governments or the 
public. 
  The optimum outcome would be complete 
exclusion of provisions that impact the cost of 
medicines from the TPP. 
  If such provisions are included, ensure TPP 
IP provisions do not extend the monopoly 
rights of pharmaceutical companies further, or 
reduce the flexibility available to governments 
further than the provisions of the World Trade 
Organisation’s TRIPS Agreement*.
  Actively prevent the practice of ‘evergreening’ § 
within the TPP.
  Ensure the TPP does not constrain the listing 
and pricing mechanisms of the PBS.
  Apply a public interest test to anti-competitive 
practices.
2. Keep patient co-payments for the PBS as low as 
possible to ensure the affordability of medicines.
3. Actively support and preserve the PBS.
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Provisions in the TPP may have an impact on the 
capacity of Government to introduce new progressive 
tobacco control policies, such as tobacco advertising 
restrictions. This section assesses how potential 
limitations to progressive advertising restrictions as 
a tobacco control measure may impact health. The 
specific policy scenarios assessed are:
1. A change in tobacco marketing restricted by the 
Federal government.
2. A change in tobacco marketing restricted by State/
Territory governments.
It is important to note that TPP provisions may impact 
plain packaging policies in countries where they have 
not already been adopted. As plain packaging is already 
in place in Australia, this section only assesses how TPP 
provisions can impact other tobacco control policies.
Current status of tobacco use in Australia and 
related health effects
Smoking is currently Australia’s largest cause of 
preventable death and illness.53-55 Over 8% of the 
disease burden in the general population is attributable 
to smoking, and it is responsible for 20% of deaths 
in Aboriginal and Torres Strait Islander peoples.56-58 
In 2013, nearly 13% of the adult population smoked 
daily.59 In 2011, nearly 14% of non-Aboriginal and Torres 
Strait Islander women and over 50% of Aboriginal and 
Torres Strait Islander women smoked while pregnant.60 
People from rural and remote regions are also twice as 
likely to smoke than their urban counterparts.59
The prevalence of smoking in Australia has steadily 
declined over the past 30 years from as high as 37% in 
1977, yet it has not declined for all population groups, 
including the Aboriginal and Torres Strait Islander 
communities.56, 61 It was estimated that the social 
cost - through lost productivity, healthcare costs and 
others - of smoking in Australia in 2005 was over $31 
billion.55, 62 Tobacco use also has independent costs for 
individual States and Territories. In NSW it is estimated 
that tobacco-related disease causes 5,000 premature 
deaths, 44,000 hospitalisations, and $8 billion in social 
costs each year.63 
Tobacco use is a major risk factor for various forms 
of cancer and chronic disease. Tobacco has been 
associated with cancer of the bladder, cervix, 
oesophagus, kidney, larynx, lungs, oral cavity, pancreas, 
stomach; and leukaemia. Tobacco is also associated 
with cardiovascular disease, respiratory disease, 
reproductive effects, cataracts, hip fractures, low bone 
density, peptic ulcer disease, and diminished health 
status.64
How a change in Federal tobacco advertising 
policies could affect health 
Current tobacco advertising policies
Many provisions in the TPP, such as an ISDS mechanism 
or cross-border services, may impact on the capacity 
of Government to introduce new progressive tobacco 
control policies, such as tobacco advertising restrictions. 
Advertising and marketing restrictions have been 
shown to be an effective policy for reducing tobacco 
How the TPP could affect Tobacco Control
Figure 3 Tobacco control pathway
  Federal tobacco advertising restrictions
  State/Territory advertising restrictions
Policy
Scenario
  Smoking prevalenceHealth 
Determinants
  Tobacco-related health outcomes (cancer, 
respiratory diseases, cardiovascular disease, 
reproductive effects, cataracts, low bone density)
  Declining health status
  Disability
  Death
Health 
Outcomes
  Investor-state dispute settlement
  Technical barriers to trade chapter
  Rules related to trademarks in the intellectual property chapter
  Other protections for investors
  Regulatory coherence chapter 
  Cross-border services chapter
TPP 
Provisions
  Low socioeconomic 
status
  Aboriginal and Torres 
Strait Islander peoples
  Homeless
  People with mental 
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related harm. In recent years the Commonwealth has 
adopted many progressive smoking prevention policies 
and strategies and has demonstrated a commitment 
to a reduction in smoking prevalence through broad 
tobacco control measures. Many of these have been 
public policy measures – the cumulative effect of which 
has been to achieve consistently declining rates of 
tobacco use. 65-67 
Recently, Australia showed international leadership in 
introducing plain packaging on tobacco containers, 
adding to the range of existing tobacco control policies. 
Plain packaging is the removal of colours, logos, and 
other marketing materials from tobacco containers, 
and the placement of enlarged graphic health 
warnings.68 Research has shown that limiting package 
design decreases perceptions about the desirability of 
smoking.69-71 Using tobacco packages to display health 
warnings has been shown to increase awareness of 
the health effects of smoking and increase cessation 
behaviour.53, 70, 72-77
Australia has had a ban on all tobacco television 
and radio advertising since 1976, and on all print 
media since 1989. In 2000, Federal legislation made 
Australia one of the first countries to regulate tobacco 
sponsorship of international sporting and cultural 
events.78 However, not all components of tobacco 
advertising are federally regulated. Despite these 
restrictions tobacco manufacturers continue to 
creatively access audiences through alternative forms 
of media. Tobacco advertising in pre-movie promotions 
is prohibited, yet audiences are still exposed to pro-
smoking imagery within films.78 Internet, mobile and 
social media marketing are also unregulated and are 
particularly effective at targeting youth.79
Electronic cigarettes, also known as e-cigarettes or 
electronic nicotine delivery systems (ENDS), are devices 
for making mists for inhalation that usually simulate 
the act of cigarette smoking. E-cigarettes can contain 
non-nicotine or nicotine fillers, and although the latter 
are not currently legal in Australia, there is anecdotal 
evidence that their use is proliferating, primarily 
through the purchase of unregulated products. 
Aggressive marketing – particularly through online, 
mobile and social media platforms – has helped to drive 
the rapid uptake of such products both in Australia and 
overseas. E-cigarettes are sometimes marketed as an 
option to help people quit smoking, or as a tobacco 
replacement, although the evidence base for this is 
limited and inconsistent.80
Although e-cigarettes that contain nicotine have not 
been registered for lawful use under the Therapeutic 
Goods Administration (TGA), major tobacco companies 
are investing heavily in e-cigarettes as a product line 
and there is anecdotal evidence that they are deploying 
sophisticated marketing strategies mirroring those 
previously used to glamorise and promote smoking to 
young people. Given electronic cigarettes are designed 
to simulate the act of smoking, there is a risk that this 
trend may re-normalise and re-glamorise the act of 
smoking more broadly. In this way, the marketing 
of e-cigarettes and their growing popularity has the 
potential to undermine decades of tobacco control 
campaigns and policies.80
Marketing laws and regulations surrounding 
e-cigarettes are currently underdeveloped, uneven and 
evolving in Australia. While some states and territories 
have legislation prohibiting the marketing of products 
that resemble tobacco products, there is currently no 
federal legislation that specifically prohibits or regulates 
such marketing. Laws relating to therapeutic goods 
do not cover the importation and sale of non-nicotine 
electronic cigarettes that do not make therapeutic 
claims. Accordingly, such products can be imported 
and sold by retailers without needing to comply with 
(Federal) laws relevant to therapeutic goods, including 
laws that apply to the packaging, marketing and 
advertising of therapeutic products.
Tobacco companies are currently lobbying Australia’s 
TGA to allow them to market e-cigarettes.81
Evidence for further tobacco advertising restrictions
Without restrictions from TPP provisions, there is 
evidence to support further measures to restrict 
tobacco advertising by the Commonwealth. Quit 
ratios are the highest in those countries with the 
most developed tobacco control policies.66 Innovative 
policies, such as the plain packaging strategy, are 
important for protecting public health by reducing the 
uptake of smoking and encouraging current smokers 
to quit.67, 72, 73, 76-79, 81-83 There is evidence to support the 
introduction of tobacco control measures in addition to 
plain packaging. The WHO’s Framework Convention on 
Tobacco Control (FCTC) places a priority on eliminating 
tobacco advertising, promotion and sponsorship, 
recognising that this would reduce the consumption 
of tobacco products.82 Article 13 requires the parties 
to the convention to implement a comprehensive ban 
on tobacco advertising, promotion and sponsorship, 
subject to constitutional limitations. The guidelines 
for implementation of Article 13 emphasise the 
importance of comprehensive bans, as anything less 
will allow the tobacco industry to continue to exploit 
loopholes. Evidence suggests that a comprehensive 
set of tobacco advertising bans can reduce tobacco 
consumption and that a limited set of advertising bans 
will have little or no effect.83 84
Australia currently has strong restrictions on tobacco 
advertising, however there are some remaining 
loopholes.  The Australian Preventative Health 
Taskforce Tobacco Work Group recommended that the 
Commonwealth amend legislation to address tobacco 
advertising, including:
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  Preclude sales through vending machines, the 
internet, and at hospitality and other social venues.
  Give government power to regulate design, 
contents and maximum emissions for tobacco 
and related products, and establish a regulatory 
body with responsibility for specifying required 
disclosure to government, labelling and any other 
communication to consumers.84
A recent WHO report on e-cigarettes expresses 
concerns that e-cigarette advertising could undermine 
tobacco control measures such as advertising bans and 
recommends “all legislation and regulations related to 
ENDS should be adaptable in response to new scientific 
evidence, including evaluation of different models 
for ENDS regulation, as evidence accumulates…Any 
form of ENDS advertising, promotion and sponsorship 
must be regulated by an appropriate governmental 
body. If this is not possible, an outright ban on ENDS 
advertising, promotion and sponsorship is preferable 
to the implementation of voluntary codes on ENDS 
marketing, given the overwhelming evidence that 
similar codes for tobacco and alcohol products have 
failed to protect young people from such advertising”.80 
Despite significant efforts from the Federal government 
to control tobacco use, there is evidence that further 
tobacco advertising policies are needed.
How a change in state/territory tobacco 
marketing policies affects health 
Current tobacco marketing policies in States and 
Territories
In Australia responsibility for control over tobacco 
advertising and marketing is split between the 
Commonwealth and States and Territories. Each State 
and Territory has its own laws relating to the restriction 
of advertising and promotion of tobacco. The NSW 
Public Health (Tobacco) Act 2008, for example, restricts 
displays of tobacco and non-tobacco smoking products 
so that they cannot be on display to the public.85 While 
all States and Territories ban point-of-sale advertising 
and promotions, contests, and giveaways, each State 
and Territory varies in prohibition of mobile tobacco 
sales, vending machines, and display ban exemptions.86
Evidence for further State/Territory Tobacco 
marketing restrictions
There is sufficient evidence that further marketing 
restrictions, unhindered by TPP restrictions, would be 
beneficial to health. Restricting tobacco point-of-sale 
advertising has been shown to be effective for reducing 
tobacco harm, particularly on youth.87-90 Display bans 
have also been found to have an impact on smoker’s 
behaviour.91 One study found that over 25% of smokers 
purchased cigarettes on impulse after seeing a cigarette 
display, and over 31% of smokers thought the removal 
of displays would make it easier for them to quit.92 
Tobacco promotions also have an important impact on 
smoking uptake. A study found that greater exposure to 
promotions lead to a higher risk of smoking.93 Based on 
the evidence, there is sufficient reason why States and 
Territories would consider further expanding tobacco 
marketing restrictions. 
Equity consideration: How tobacco advertising 
and marketing affect certain populations
There are considerable disparities in tobacco use 
amongst various disadvantaged populations. Smoking 
rates among Aboriginal and Torres Strait Islander 
communities are more than double those in the rest 
of the population.53, 55, 56 Rates of smoking are also high 
amongst vulnerable populations such as homeless 
people,94 people who use drugs,95 incarcerated 
people,53 people with low socioeconomic status (SES),53, 
55 people with mental illness96 and people in rural and 
remote regions.59 Despite population-level decreases, 
smoking prevalence has declined least in the most 
disadvantaged communities.53
There are particular equity considerations for youth 
from tobacco control measures. Children in low SES 
households are more than four times more likely to be 
exposed to smoke in the home than children of higher 
SES households.53 Youth are particularly susceptible to 
tobacco advertising and have therefore been positively 
impacted by plain packaging legislation.65, 77, 79, 97-102 
Tobacco promotions and point-of-sale advertising are 
also particularly influential on youth.103 Studies have 
shown that promotions may have a greater influence 
on youth than exposure to peer and family smoking or 
sociodemographic variables.104, 105
Overall, broad level policies have been shown to 
be most effective in reducing inequities in smoking 
prevalence.106 During periods of low funding for 
tobacco control measures in Australia, smoking 
prevalence increased in certain populations with the 
greatest increase among low SES groups. In contrast, 
during periods of high funding, smoking decreased 
sharply with consistent decreases amongst all SES 
groups.53 Advertising bans have also shown the 
potential to reduce socioeconomic inequalities in 
smoking.107
Provisions proposed for the TPP that have 
implications for tobacco control
Many chapters of the TPP could affect tobacco control 
policies in Australia. The summary below focuses on the 
chapters most commonly identified by legal experts as 
presenting problems for tobacco control. Importantly 
multiple chapters may interact, with amplified effects.108
A leaked draft of the investment chapter of the TPP51 
shows that it includes an ISDS mechanism. The tobacco 
industry has used similar mechanisms in other trade 
and investment agreements to sue the governments 
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of Australia and Uruguay over their strong tobacco 
control measures.109 Philip Morris Asia is using the ISDS 
clause in an investment agreement between Australia 
and Hong Kong to seek compensation (possibly 
amounting to billions of dollars) over its tobacco plain 
packaging laws.110 While the government is expected to 
win this case, an ISDS clause in the TPP would provide 
more opportunities for tobacco companies to sue. 
The current Government has made it clear that it is 
prepared to negotiate an ISDS mechanism applying to 
Australia.111 
The leaked draft TPP investment chapter51 also includes 
other protections for investors including rules about 
‘indirect expropriation’ (i.e. depriving an investor of 
property, which, if broadly defined, can include IP such 
as trademarks) and ‘fair and equitable treatment’. These 
rules provide additional grounds for corporations to 
argue that their assets are being unfairly affected by 
government policies and laws.112, 113 For example, Philip 
Morris Asia is claiming that the Australian Government 
has expropriated its IP by preventing it from 
displaying trademarks and other branding on tobacco 
packaging.110 ISDS may be used by tobacco companies 
in the future to challenge tobacco control policies other 
than plain packaging.
Rules related to trademarks in the intellectual 
property chapter of the TPP42 may be interpreted to 
provide greater rights to tobacco companies to use 
their trademarks than those provided by the World 
Trade Organization (WTO).114 This could provide 
grounds for industry challenges to the removal of 
branding from products (as in tobacco plain packaging) 
or potentially other forms of tobacco advertising. 
Provisions in the Regulatory Coherence Chapter46 
include requirements for governments to provide 
opportunities for stakeholder input into policy-making. 
The Transparency Chapter could also reinforce these 
opportunities.108 This potentially undermines the 
requirement of the WHO’s FCTC82 that tobacco control 
policies be protected from tobacco industry interests. 
Provisions in the chapter on Cross-border Services 
may affect services related to the packaging, sale, 
distribution and advertising of tobacco products and 
e-cigarettes.112 These provisions might affect tobacco 
control policies such as bans on advertising, or licensing 
of retailers and distributors,112 policies which have 
proven effectiveness. 
The Technical Barriers to Trade chapter may also affect 
the way governments set tobacco control regulations, 
standards and guidelines.112
In 2013, the Malaysian Government tabled a proposal 
to “carve out” (i.e. exclude) tobacco from the TPP.115 This 
would mean any of the provisions in the TPP would not 
apply to tobacco control measures (such as tobacco 
plain packaging). However, reports suggest that the 
Australian government is not supporting this proposal.
Impact prediction
There are several provisions in the TPP that could 
restrict the ability of State and Federal governments 
to implement further tobacco control measures. Given 
the effectiveness of tobacco advertising and marketing 
restrictions, as discussed above, it is likely that TPP 
provisions that hinder the ability of Government to 
implement these types of policies will have a negative 
impact on health. There is strong evidence that 
tobacco advertising restrictions reduce tobacco use 
rates, and limitations to advertising restrictions would 
negatively impact health, particularly for vulnerable 
populations such as Aboriginal and Torres Strait Islander 
communities, and youth.
Recommendations
In order to avoid negative impacts to health associated 
with restrictions to tobacco control measures, we 
recommend the following:
1. Ensure the provisions of the TPP do not limit 
the capacity of governments to introduce and 
implement priority interventions to maintain or 
improve public health, particularly for tobacco 
control.
2. Given the harmful effects of tobacco, exclude 
from the TPP these products, policies and laws 
to regulate them, and any services or investment 
related to their advertising and promotion, 
distribution, etc.
3. Make explicit in the TPP that where there might be 
any potential conflict between a Party’s obligations 
under the FCTC and the TPP, the FCTC would have 
precedence.
4. Adopt interventions, which are part of a 
comprehensive suite of activities to achieve the 
health outcome (for example, tobacco advertising 
restrictions as one policy within a suite of tobacco 
control interventions).
5. Invest research dollars and resources in developing 
the evidence base for public health interventions, 
particularly in relation to tobacco.
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How the TPP could affect Alcohol Control
Provisions from the TPP may impact the Government’s 
ability to implement effective alcohol control policies 
related to alcohol marketing and availability. This 
section assesses the potential health impacts from TPP 
provisions to the following policy scenarios: 
1. Restrictions on alcohol availability;
2. Bans or limits on alcohol advertising; and 
3. Pregnancy warning labels. 
Current status of alcohol use in Australia and 
related health effects
Alcohol contributes towards 4% of the world’s disability 
adjusted life years, or years lost due to alcohol-related 
injury or death, and 3.2% of worldwide mortality.56, 58, 116 
Alcohol is associated with significant long term health 
effects to the brain, heart, liver and other organs, as well 
as social and psychological impacts.117 In the short term, 
alcohol use relates to risk of injury for both the drinker 
and others.118
In Australia 18.2 % of the population are at risk for 
alcohol-related injury or illness over their lifetime 
based on their current rates of alcohol consumption.119 
Nearly 5 million Australians report being the victim of 
an alcohol related incident, such as verbal or physical 
abuse.119 Approximately 1 in 5 drinkers report taking 
part in a potentially harmful activity while under the 
influence.59 Only fifty-three percent of pregnant women 
abstain from drinking while pregnant and only 34% of 
breastfeeding women also abstain.66, 119
The overall social and economic costs of alcohol misuse 
to the Australian community are estimated to be over 
$15 billion per annum.62
How restrictions on alcohol availability affect 
health
Current alcohol availability policies
Provisions from the TPP, such as the technical barriers 
to trade chapter and the wine and spirits annex, may 
impact the Government’s ability to implement effective 
alcohol control policies. Restricting the availability 
of alcohol - through limits on alcohol outlet density 
and trading hours - is one mechanism that may be 
impacted by provisions, and has been shown to be 
effective in reducing alcohol-related harm. Licensing is 
one measure that can be used to restrict consumption 
of alcohol through limiting the hours or days alcohol is 
available for purchase. State and Local governments are 
responsible for the liquor licenses, planning laws and 
other restrictions that impact alcohol outlet density. 
Over the past few decades a relaxation in alcohol 
licensing laws has led to a significant growth in 
alcohol outlets throughout Australia.120 Much of this 
policy relaxation has been in response to the National 
Competitive Policy (NCP), which requires regulatory 
policies to demonstrate high levels of efficacy. One of 
the key policies targeted as an area of concern under 
the NCP is outlet density. The current priority given by 
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the Commonwealth to the NCP has created tensions in 
the state-level implementation. For example, both New 
South Wales and Western Australia were fined in 2003 
after refusing to meet regulations that required de-
regulation of the alcohol industry.121 
Evidence for regulation of alcohol availability
Without restrictions from trade provisions in the TPP, 
there is evidence that further regulation of alcohol 
outlet density is beneficial for health. Systematic 
reviews and meta-analyses show that policies 
regulating the environment in which alcohol is 
marketed, particularly its price and availability, are 
effective and cost-effective in reducing alcohol-related 
harm.122, 123 Alcohol outlet density has been found 
to have an association with drink-driving and motor 
vehicle accidents124-126; pedestrian injury127; child 
maltreatment128, 129; and rates of sexually transmitted 
infection.130 A study in Perth found that extending the 
trading hours for sale of alcohol was associated with an 
increase in the level of violent assault.131 Some evidence 
has shown that alcohol outlet density impacts rates of 
violence.132 In one study, the authors estimated that 
an average reduction of one bar for each of the 581 
postal codes analysed would have resulted in 209 fewer 
assaults.133 Generally evidence has shown that increases 
in the availability of alcohol lead to higher rates of harm 
and that reducing outlet density may reduce risks of 
harm.121, 133-135
How restrictions on alcohol marketing affect 
health
Current regulation of alcohol advertising
Some provisions in the TPP may also have an impact 
on the ability of Government to regulate alcohol 
marketing. Alcohol advertising is currently subject to a 
combination of regulatory (mandated by Government), 
co-regulatory and self-regulatory frameworks. Unlike 
tobacco advertising, which is subject to legislated and 
much more comprehensive provisions, Government 
involvement in regulating alcohol marketing is limited 
to the times that such advertising can be broadcast on 
television. Specifically, television broadcasts should not 
be during children’s viewing times, with the exception 
that alcohol advertisements are allowed during live 
broadcasting of sporting events on public holidays and 
weekends.136 Voluntary regulations, administered by the 
alcohol industry, apply to other dimensions of alcohol 
advertising and apply to the content and, to a limited 
extent, the placement of advertisements. Existing 
evidence suggests that Australian adolescents, despite 
these restrictions, are exposed to high levels of alcohol 
advertising particularly during television watching.136 
Evidence for further regulation of alcohol marketing
There is evidence to show that legislated and stronger 
regulation of alcohol marketing can reduce harmful 
alcohol consumption and thereby improve health 
outcomes. Alcohol marketing – via mainstream media, 
linking alcohol to social and sporting events, and 
direct marketing campaigns – has been shown to 
influence whether people drink and how much they 
drink.137 Banning of alcohol advertising, drink-driving 
countermeasures, licensing controls and individually-
directed interventions to drinkers already at risk are 
considered cost-effective approaches.122, 138
How pregnancy warning labels affect health
Current pregnancy warning label policies
Provisions in the TPP related to alcohol marketing 
and labelling, such as the wine and spirits annex and 
the IP chapter, may have an impact on the ability of 
Government to implement pregnancy warning labels. 
Current regulations require alcohol containers to 
display the alcoholic strength of the beverage, but do 
not require any further health or nutritional labelling.139 
In recent years the alcohol industry has voluntarily 
implemented its own educational label, developed by 
the alcohol industry organisation DrinkWise. There has 
been criticism from the public health community that 
these voluntary labels do not meet the requirements 
to affect behavioural change in consumers.139 This 
is because the labels are small, the messaging is 
ambiguous and are often not prominent.
Currently, there is no mandatory requirement for 
displaying pregnancy warning labels on alcoholic 
containers. Alcohol manufacturers may voluntarily 
include pregnancy warning labels, but a recent review 
found that only 38.2% of alcohol products contained 
a warning label.140 An Independent Review of Food 
Labelling Law and Policy, which was commissioned 
by the Australia and New Zealand Food Regulation 
Ministerial Council in October 2009, recommended that 
alcohol labels include warning messages about the 
risks of consuming alcohol while pregnant.139 However, 
the Council did not pursue this recommendation on the 
grounds that “requiring a Nutrition Information Panel 
on mixed alcoholic beverages could have unintended 
health consequences, international trade considerations 
and impose additional costs on the alcohol industry”.139 
(emphasis added)
Evidence for pregnancy warning labels
Without any further external restrictions, there is 
support from policy experts for the inclusion of 
pregnancy warning labels. The National Health and 
Medical Research Council recommends that women 
abstain from consuming alcohol while pregnant.141 
There is sufficient evidence to demonstrate that 
drinking alcohol while pregnant can damage the 
foetus, and completely abstaining from alcohol is 
the safest option.141 Furthermore an expert panel 
recommends that warning messages about the risks of 
drinking alcohol while pregnant should be mandated 
on alcoholic containers.142 
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Equity consideration: How alcohol control 
policies affect certain populations
There are apparent differences in alcohol consumption 
among various populations. People living in remote or 
very remote areas are two times more likely to consume 
alcohol at risky levels.59 While risky alcohol use has 
decreased in urban areas, there has been no significant 
change in alcohol use among people in remote 
areas.59 Although Aboriginal and Torres Strait Islander 
populations are more likely to abstain from drinking 
versus non-Aboriginal and Torres Strait Islander groups, 
they are also 1.5 times more likely to consume alcohol 
at risky levels.59, 66 People with higher SES are more likely 
to drink at high-risk levels than people with lower SES, 
yet people with lower SES have higher rates of death 
and disability due to alcohol.66, 137 There is evidence that 
low SES populations are more likely to be influenced by 
alcohol outlet density.143 This implies that increases to 
alcohol outlet density may adversely impact vulnerable 
populations. 
Adolescents are particularly sensitive to alcohol control 
measures. Recent evidence found an association 
between alcohol outlet density and increased alcohol 
consumption in adolescents.144 Adolescents are also 
particularly susceptible to alcohol marketing.136 
Evidence shows that exposure to alcohol marketing and 
promotions increases the likelihood that adolescents 
will start or increase their use of alcohol.122
It is unclear to what extent alcohol pregnancy warning 
labels impact various populations. The incidence rate 
of foetal alcohol spectrum disorders (FASD) is uncertain 
as there are not routine diagnoses for the condition.145 
However current rates of FASD indicate a higher 
prevalence in Aboriginal and Torres Strait Islander 
communities. The incidence rate of foetal alcohol 
syndrome is between 2.76 and 4.7 births per 1,000 in 
Aboriginal and Torres Strait Islander populations, four 
times higher than the foetal alcohol syndrome rate in 
the general population.145
Provisions proposed for the TPP that may have 
implications for alcohol regulation
There are several provisions in the TPP that may have 
an impact on alcohol control measures. In particular, 
there are several ways in which the provisions may 
enact to restrict alcohol marketing, outlet density, and 
pregnancy warning labels regulation.
If provisions in the TBT Chapter of the TPP repeat, or 
extend beyond those in the WTO’s TBT Agreement, 
it may be more difficult for countries to make a case 
for introducing innovative alcohol policies, such as 
requiring health warning labels, limiting the health or 
other claims which alcohol manufacturers can make 
about their products, or restricting the alcohol content 
of certain products. This is likely to be a problem 
where the evidence base for the intervention is still 
developing.113
Provisions in the wine and spirits annex to the TBT 
Chapter may limit the options available to create a 
fully effective alcohol warning scheme for wine and 
spirits. If it allows manufacturers to meet the labelling 
requirements of the importing country by putting 
a ‘supplementary label’ on the container, this may 
effectively prevent governments from mandating an 
effective warning scheme.146
Rules related to trademarks in the IP Chapter of the 
TPP42 may be interpreted to provide greater rights to 
alcohol companies to use their trademarks than those 
provided by the WTO. This could provide additional 
barriers to implementation of an effective health 
warning system. 
Rules included in the Cross-Border Services Chapter 
may prohibit governments from introducing bans or 
limits on the number and size of services supplied 
across borders.113 This might affect State and Territory 
attempts to restrict the number of licensed alcohol 
outlets per geographic area. It might also inhibit the 
government from restricting alcohol advertising, 
particularly advertising via the internet or from 
broadcasters outside Australia.
If Australia agrees to an ISDS mechanism applying 
to Australia, the alcohol industry will have access to a 
new legal channel to sue the Australian Government 
over alcohol policy decisions that adversely impact 
their investments.  Investor protections may extend 
to trademarks, licenses and distribution agreements 
as well as direct investment in alcohol manufacturing, 
retail and distribution.113 
The general exceptions for the TPP are likely to be 
based on the WTO exceptions. While these exceptions 
can be helpful in some disputes, they do not prevent 
disputes being raised. Limits in the evidence base 
(which necessarily exist with novel public health 
interventions) might create difficulties in using the 
exceptions.
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Impact prediction
There are several provisions in the TPP that could 
restrict the ability of Government to implement further 
alcohol control measures. Given the public health 
evidence that Government policies on pregnancy 
warning labels, alcohol availability, and alcohol 
marketing have on reducing harmful consumption of 
alcohol, it is likely that any TPP provisions that hinder 
the ability of Government to implement these policies 
will negatively impact health. Without progressive 
alcohol harm reduction policies it is likely that harmful 
consumption rates will continue with subsequent 
negative impacts on the population, particularly for 
vulnerable groups such as low SES, Aboriginal and 
Torres Strait Islander communities, and youth.
Recommendations
In order to avoid negative impacts to health associated 
with restrictions to alcohol control measures, we 
recommend the following:
1. Ensure the provisions of the TPP do not limit 
the capacity of governments to introduce and 
implement priority interventions to maintain or 
improve public health, particularly for reducing 
harmful use of alcohol.
2. Given the harmful effects of excessive consumption 
of alcohol, exclude from the TPP these products, 
policies and laws to regulate them, and any services 
or investment related to their advertising and 
promotion, distribution, etc.
3. Adopt interventions, which are part of a 
comprehensive suite of activities to achieve the 
health outcome (for example, pregnancy alcohol 
warning labels as one policy within a suite of 
alcohol harm reduction interventions).
4. Invest research dollars and resources in developing 
the evidence base for public health interventions, 
particularly in relation to alcohol.
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How the TPP could affect Food Labelling
Provisions from the TPP may impact the Government’s 
ability to implement food nutrition labelling policies. 
This section assesses the potential impacts that a 
restriction on food labelling from TPP provisions would 
have on health. 
Current status of unhealthy food consumption 
in Australia and related health effects
Obesity and overweight are major risk factors for heart 
disease, diabetes, liver disease, and increase the risk 
for nearly every other chronic disease.147 Heart disease 
is the current leading cause of death of Australians. 
In 2011, ischaemic heart disease represented 14.6% 
of all deaths.148 Excess body weight increases the 
risk of cardiovascular disease (CVD) such as heart 
attack and stroke. People who are obese are nearly 
five times as likely to have risk factors for CVD, such 
as high triglycerides and low HDL cholesterol levels, 
as normal-weight adults.147 Obesity also increases 
insulin resistance which can lead to the onset of type 2 
diabetes.149 In 2012, 5.1% of Australians had diabetes. 
Obese adults are seven times more likely to have 
diabetes than normal-weight adults, and around 1 in 20 
is at risk to develop diabetes.147 Excess body fat is also 
a risk factor for liver disease. In 2012, people who were 
obese were four times more likely than those of normal 
weight to have liver disease risk markers.147
In 2012, 63% of Australians over age 18 were either 
overweight or obese.61 Among developed nations, as 
of 2012, Australia ranks seventh for rates of obesity 
with more than 1 in 4 adults now obese.150 Obesity 
alone cost the healthcare system approximately $2 
billion in direct costs in 2008.150 In 2012, data from the 
National Heath Survey showed that less than half of 
those surveyed reported consuming recommended 
quantities of fruit and only 8% met the recommended 
quantity of vegetables.67 
How changes to regulation of food labelling 
affect health
Current food labelling policies
TPP provisions, such as the ISDS mechanism or 
TBT chapter, may have an impact on food labelling 
policies in Australia. In particular, these provisions may 
prevent the implementation of more progressive food 
labelling policies by regulatory organisations. With 
global rates of obesity increasing, the WHO has set out 
policy recommendations for addressing this growing 
risk factor for non-communicable diseases (NCDs). 
The WHO Global Action Plan for the Prevention and 
Control of NCDs 2013-2020 lays out a menu of policy 
options for member states to consider to help halt the 
increase of obesity, including improved nutritional 
labelling of processed and ready-to-eat foods.151 The 
WHO supports the use of nutritional labelling as a 
mechanism to inform consumers about what they are 
purchasing and to make healthier decisions.151 Australia 
follows food nutrition labelling guidelines as set out 
by Food Standards Australian New Zealand (FSANZ). 
Since 2006, manufacturers have used the daily intake 
guide (DIG) – a nutrition labelling system designed 
by the food industry. The DIG provides information 
about the contribution of serving nutrition towards a 
person’s average intake. Most manufacturers of energy-
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dense food products have adopted DIG labelling to 
include energy intake while not necessarily including 
information on saturated fats and sugar.152 Recently 
the FSANZ supported manufacturers to voluntarily 
include new Health Star Rating (HSR) labels to their 
products, starting in June 2014.153 HSR is different from 
DIG in that it provides consumers with an at-a-glance 
nutrition value using a star rating scale, with the most 
nutritional foods having more stars. Both systems are 
self-regulated by industry with the Commonwealth 
deferring to industry standards in the promotion of 
food labelling policies. As a whole, industry has been 
resistant to adopting a single, mandatory labelling 
system.142
Evidence for improved food labelling
There is public health evidence that requiring more 
comprehensive nutrition labels is beneficial for health. 
Nutrition experts have criticised DIG labelling for being 
confusing to consumers and not meeting basic health 
education requirements.154-156 In order to make nutrition 
labels more accessible for the general population, 
and particularly for groups such as children and low-
literacy adults, nutrition experts have advocated for 
the use of clear, graphic systems like HSR on front of 
packages.157-160 Likewise, consumers often support the 
use of consistent formats of food labelling and when in 
use, have been found to identify healthier foods.155, 157, 161
However, HSR food labelling is just one policy strategy 
in a suite of interventions to address obesity-related 
disease. Food labelling alone does not always lead 
to healthy food consumption, and nutrition experts 
argue that the overall efficacy of food labelling should 
be assessed as part of a set of interventions, rather 
than on its own.142 Provisions in the TPP that restrict 
the implementation of labels or require assessment 
of public health interventions in isolation would likely 
limit the ability of regulators to implement improved 
food nutrition labels. 
Equity consideration: How food labelling 
impacts certain populations
There are equity differences in the distribution of 
obesity rates and access to healthy foods. Low SES 
and certain culturally and linguistically diverse (CALD) 
populations are associated with higher body mass 
index (BMI), and low SES has been shown to have 
an independently associated risk with obesity.162 
In Australia, the prevalence of obesity in the least 
advantaged areas is four times that of the most 
advantaged areas.150 Likewise, obesity rates are 
higher in geographically remote areas than they 
are in Australian major cities or regional areas.61 
Socioeconomically disadvantaged populations may 
have a greater need for healthy food promotion policies 
as they are more likely to have lesser access to healthy 
foods and greater availability of unhealthy retailers such 
as fast food and convenience stores.162-169 Aboriginal 
and Torres Strait Islander populations are also more 
likely to be obese than non-Aboriginal and Torres Strait 
Islander populations with 31% of males and 37% of 
females being categorised as obese.61
Likewise, there are inequalities in population groups 
around the use of nutrition labelling. The 2011 
National Review of Labelling Law and Policy, amongst 
other studies, found that the DIG system is generally 
confusing, and particularly inappropriate for consumers 
with low literacy.142, 154, 161, 170 Low-income consumers, 
people with low levels of education, youth, and 
elderly obese adults are more likely to have difficulty 
understanding food labels and are therefore less likely 
to use them.156, 157, 171 Therefore, interpretive labelling is 
likely to be most effective when it involves colour and/
or simple logos that are easily understood by the most 
vulnerable population groups.172 This is likely to support 
the most widespread improvement in consumer 
awareness and efficacy for dietary change.
Provisions proposed for the TPP that may have 
implications for food labelling
Several provisions in the TPP may have an effect on 
food labelling. The summary below focuses on the 
chapters most commonly identified by legal experts 
as presenting problems for implementation of food 
labelling policies.
The ISDS mechanism could potentially be used by 
the food industry (e.g. processed food corporations, 
or corporations with roles in distribution, retail etc.) to 
sue Australian governments over efforts to regulate the 
industry.173 While investor-state clauses have not been 
utilised by the food industry to date, the food industry 
is increasingly adopting strategies used by the tobacco 
industry to exert leverage over policy making.174
The regulatory coherence and transparency chapters 
of the TPP may contain provisions that provide a greater 
role for the processed food industry in policy decision 
making, which many mean they are able to influence 
the type of food labelling systems used.173
The TBT chapter may also have implications for 
labelling of processed foods, possibly preventing 
innovations in labelling to assist consumers to 
make better food choices, such as traffic light food 
labelling.175 A priority of TBT rules is that measures 
should be evidence based and ‘not more trade-
restrictive than necessary to fulfil a legitimate objective’. 
However, in the absence of a clear international 
standard or reference on food labelling for non-
communicable diseases (NCD), the concept of ‘least 
trade restricting’ is open to interpretation. For example, 
Thailand abandoned efforts to implement traffic light 
labelling of snack foods after the US and other countries 
complained that Thailand’s proposal contravened the 
WTO’s TBT agreement.
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Commitments on cross-border advertising (a form 
of trade in services) may create barriers to regulating 
marketing of foods to children. These commitments 
are likely to include stringent criteria and evidence 
requirements for any measure that might restrict 
trade in services. The associated cost and potential 
for challenge (for example, under dispute settlement 
mechanisms) is likely to make it more difficult for 
governments to implement innovative measures in this 
area.
Impact prediction
There are several provisions in the TPP that could 
restrict the ability of regulators to require improved 
food nutrition labels. Given the documented 
effectiveness of labelling policies in enabling 
consumers to make healthier food choices, it is likely 
that provisions in the TPP that limit the implementation 
of food labelling policies will result in continuation 
of ongoing consumer trends in consumption of 
less-healthy foods. Without strong compensatory 
intervention to improve consumer awareness of the 
relative healthfulness of foods, it is likely that there will 
be no change to current high rates of obesity, metabolic 
syndrome and NCDs. This would have a negative impact 
on health, particularly for vulnerable populations, such 
as low SES and CALD groups.
Recommendations
In order to support health through enabling improved 
food nutrition labels, we recommend the following:
1. Ensure the provisions of the TPP do not limit 
the capacity of governments to introduce and 
implement food labelling interventions to maintain 
or improve public health nutrition.
2. Include wording to ensure that where any disputes 
arise under the TPP, programs and policies are 
not assessed for their efficacy as only singular 
intervention points; they must be assessed within 
the context of a comprehensive suite of activities 
to achieve the health outcome (for example food 
labelling as one intervention amongst several 
strategies to improve nutrition).
IMPACT
21
Impact Characterisation
Impact characterisations analyse potential health impacts and characterise the changes according to various 
indicators.176 We provide an estimate of the predicted impact of TPP provisions on the four pathways discussed in 
this report: 
  cost of medicines; 
  tobacco control; 
  alcohol control; and 
  food labelling.
The impact characterisations are based on public health literature and stakeholder input gathered for the 
assessment. The following indicators have been used to describe the impacts: 
Likelihood (the probability that an impact will occur)
  Speculative - may or may not happen. Plausible but with limited evidence to support.
  Possible - more likely to happen than not. Direct evidence but from limited sources.
  Likely - very likely to happen. Direct strong evidence from a range of data sources.
Direction (describes the nature of the effect)
  Positive - impacts that improve or maintain health status.
  Negative -  impacts that diminish health status.
Cost of Medicines
There is sufficient evidence that increases in the 
cost of medicines will lead to greater patient 
co-payments through the PBS. Given the public 
health evidence that increases in patient co-
payments lead to lower rates of prescription 
use, it is likely that any provisions in the TPP that 
raise the cost of medicines will have a negative 
impact on health. This is particularly relevant 
for vulnerable populations such as low-income 
patients and people with chronic conditions.
Food Labelling
Given the documented effectiveness of labelling 
policies in enabling consumers to make healthier 
food choices, it is likely that provisions in the TPP 
that limit the ability of Government to implement 
food labelling policies will result in continuation 
of ongoing consumer trends in consumption of 
less-healthy foods. Without strong compensatory 
intervention to improve consumer awareness 
of the relative healthfulness of foods, it is likely 
that there will be no change to current high 
rates of obesity, metabolic syndrome and NCDs. 
This would have a negative impact on health, 
particularly for vulnerable populations, such as 
low SES, Aboriginal and Torres Strait Islander 
communities, and CALD groups.
Alcohol Control
Given the public health evidence that 
Government policies on pregnancy warning 
labels, alcohol availability, and alcohol marketing 
reduce harmful consumption of alcohol, it is likely 
that any TPP provisions that hinder the ability 
of Government to implement these policies will 
negatively impact health. Without progressive 
alcohol harm reduction policies it is likely that 
harmful consumption rates will continue with 
subsequent negative impacts on the population, 
particularly for vulnerable groups such as low SES, 
Aboriginal and Torres Strait Islander communities, 
and youth.
Tobacco Control
Given the effectiveness of tobacco advertising 
restrictions by the Federal and State governments, 
it is likely that TPP provisions that hinder the 
ability of Government to implement these 
types of policies will have a negative impact on 
health. There is strong evidence that tobacco 
advertising restrictions reduce tobacco use 
rates, and limitations to advertising restrictions 
would negatively impact health, particularly for 
vulnerable populations, such as Aboriginal and 
Torres Strait Islander communities, and youth.
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HIA Recommendations
The HIA team held an assessment workshop with 
members of the Technical Advisory Group, Advocacy 
Advisory Group and other relevant stakeholders to 
discuss and validate the findings of the assessment 
and develop recommendations for minimising 
potential harms to health and maximising health 
benefits. The draft recommendations were then 
circulated to all those involved in the HIA process 
including subject experts for comment and 
finalisation. 
1 Recommendations to the Department of Foreign Affairs and Trade regarding TPP provisions
1.1 Ensure within the TPP text that public health concerns override economic or trade concerns in any area where 
these priorities may conflict. This means:
  including clear and strong public health exceptions; and
  defining public health as broadly as possible (e.g. not restricting the definition, explicitly or implicitly, to 
emergencies or to particular diseases).
1.2 Do not agree to provisions that potentially increase the cost of medicines for governments or the public. 
1.2.1.  The optimum outcome would be complete exclusion of provisions that impact the cost of medicines 
from the TPP. 
1.2.2.  If such provisions are included, ensure TPP intellectual property provisions do not extend the monopoly 
rights of pharmaceutical companies further, or reduce the flexibility available to governments further, 
than the provisions of the World Trade Organization’s TRIPS Agreement*. 
1.2.3. Actively prevent the practice of ‘evergreening’ § within the TPP.
1.2.4.  Ensure the TPP does not constrain the listing and pricing mechanisms of the Pharmaceutical Benefits 
Scheme (PBS).
1.2.5. Apply a public interest test to anti-competitive practices.
1.3 Ensure the provisions of the TPP do not limit the capacity of governments to introduce and implement priority 
interventions to maintain or improve public health, particularly in the following areas:
  tobacco control;
  reducing harmful use of alcohol; and
  food nutrition labelling.
These include, but are not limited to, the interventions discussed in this report.
1.4 Given the harmful effects of tobacco and excessive consumption of alcohol, exclude from the TPP these 
products, policies and laws to regulate them, and any services or investment related to their advertising and 
promotion, distribution, etc.
1.5 Make explicit in the TPP that where there might be any potential conflict between a Party’s obligations under the 
Framework Convention on Tobacco Control (FCTC) and the TPP, the FCTC would have precedence.
1.6 Exclude Investor-state dispute settlement (ISDS) from the TPP as this is a serious threat to public health policies.
1.7 However, if ISDS is included, incorporate effective safeguards in the TPP that prevent investors from making 
claims related to public health and public health service matters. (Noting that the safeguards included in the 
Korea-Australia Free Trade Agreement (KAFTA) are widely acknowledged to be insufficient to prevent claims like 
the case by Philip Morris Asia against Australia over tobacco plain packaging).
1.8 Include wording to ensure that where any disputes arise under the TPP, programs and policies are not 
assessed for their efficacy as only singular intervention points; they must be assessed within the context of a 
comprehensive suite of activities to achieve the health outcome (for example food labelling as one intervention 
amongst several strategies to improve nutrition), or compared to global standards and national strategies.
The recommendations fall into three categories:
1. Recommendations to DFAT and Government 
regarding TPP provisions;
2. Recommendations to the Australian Government 
regarding the TPP negotiating process; and
3. Broader policy recommendations to Government in 
the areas of medicines, tobacco, alcohol, and food.
* The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international agreement administered by the WTO. It 
establishes minimum standards for many forms of intellectual property (IP) regulation, including generous 20-year patent terms for genuine 
pharmaceutical innovation, and flexibilities that allow countries to protect public health interests.
§ Evergreening refers to the way in which the pharmaceutical industry seeks patents for minor modifications to existing pharmaceutical 
products (such as changes to formulations, uses and methods of delivery) in order to extend monopolies and delay generic competition.
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2 Recommendations to the Australian Government regarding the TPP negotiating process
2.1 Conduct trade negotiations with full public transparency. This means:
  publication of draft texts;
  publication of the Australian Government’s negotiating position on issues of public interest; and
  public release of the final TPP text and examination by both the Joint Standing Committee on Treaties and 
the Senate Committee on Foreign Affairs, Defence and Trade before Cabinet authorises it to be signed. This 
would enable full debate in both Houses of Parliament.
2.2 Ensure public interest stakeholders, including non-governmental health organisations, are informed of 
issues related to health and involved in a structured and organised way with sufficient prior notification for 
consultation.
2.3 Conduct Health Impact Assessments, with a focus on equity:
  after release of the final TPP text but before it is signed; and
  periodically on new policies or activities resulting from the TPP.
2.4 Apply the precautionary principle† in trade negotiations.
2.5 The Department of Health should undertake regular monitoring of the impacts on health with a particular focus 
on health equity. Ensure monitoring is carried out transparently and publicly reported.
3 Broader policy recommendations to governments in the areas of medicines, food, alcohol and tobacco
3.1 Keep patient co-payments for the PBS as low as possible to ensure the affordability of medicines.
3.2 The Australian Government should support global efforts to separate the funding of research and development 
from medicine prices.
3.3 Actively support and preserve the PBS.
3.4 Adopt interventions which are part of a comprehensive suite of activities to achieve the health outcome (for 
example, alcohol warning labels as one policy within a suite of alcohol harm reduction interventions).
3.5 Invest research dollars and resources in developing the evidence base for public health interventions.
3.6 Develop clear criteria for protecting and prioritising equity in health policy development; this will help to justify/
support strong, effective and equitable public health policy options.
† The precautionary principle refers to protective action in the absence of scientific evidence. In situations where there is the potential 
for harm, but there is uncertainty about the magnitude of the impact or causality, then only action to avoid harm or no action should 
be undertaken. See Raffensperger, C. and Tickner, J.A . Protecting public health and the environment: implementing the precautionary 
principle. Washington, D.C: Island Press, 1999.
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Conclusion
Based on a review of the literature, expert advice and 
leaked negotiating documents for the TPP, the HIA 
established that there is potential for negative impacts 
on the health of Australians in each of the four areas 
under investigation. 
The TPP risks increasing the cost of the PBS, which 
is likely to flow on to the Australian public in terms 
of increased co-payments (out-of-pocket expenses) 
for medicines. This may result in medical non-
adherence for prescription use and prioritising 
health costs over other necessities (food, housing, 
etc.). Vulnerable groups include those from low SES 
backgrounds, people with chronic conditions, younger 
populations, and Aboriginal and Torres Strait Islander 
populations. Potential risks to health outcomes include 
declining health status in the community, increased 
hospitalisations and premature or preventable 
mortality.
The TPP provisions pose risks to the ability of 
Government to regulate and restrict tobacco 
advertising. This could potentially lead to increased 
tobacco use and smoking prevalence, resulting in 
increases in tobacco related health harms across the 
community but particularly for existing vulnerable 
groups, such as youth and people with low SES.
Some provisions proposed for the TPP have the 
potential to limit regulation of alcohol availability 
and alcohol marketing, and restrict alcohol control 
measures such as pregnancy warning labels. This risks 
increasing alcohol consumption rates and abuse, 
especially amongst young members of the community. 
This may lead to increased alcohol related disorders, 
worsening mental health and social disruption in the 
community.
There is the potential for TPP provisions to restrict 
the ability of Government to implement new food 
labelling policies, limiting reductions in consumption 
of unhealthy foods. This is associated with rates of 
overweight/obesity and related poor health outcomes.
The extent to which these risks are realised in the final 
text of the TPP remains to be seen, as the agreement 
is yet to be finalised. Some of the key issues of 
concern to health advocates are yet to be resolved 
in the negotiations. In addition, it is not possible to 
guarantee public health objectives are safeguarded 
in the absence of systematic expert analysis of 
the proposed agreement. Trade negotiations that 
simultaneously cover several sectors can easily lead to 
more extensive commitments than may be intended. 
Irrespective of the Government’s intent, the detail and 
minutiae of trade agreements can include provisions 
that have unanticipated consequences for public 
health policy. Accordingly, the sheer breadth and 
complexity of the agreement necessitates meticulous 
expert scrutiny to identify provisions that may directly 
or indirectly compromise public health outcomes. This 
report makes a number of recommendations to the 
Australian Government intended to prevent or mitigate 
the realisation of these risks.
This HIA is necessarily limited due to the lack of 
transparency in the negotiations and the difficulties in 
obtaining detailed information about the current state 
of the negotiating text. It also does not capture the full 
range and extent of potential public health impacts, but 
nevertheless demonstrates the potential for significant 
adverse outcomes in some key areas that are a priority 
in maintaining and improving the health of Australians.
We recommend that an independent and 
comprehensive HIA is undertaken when the final text 
of the TPP is made publicly available, and before it is 
signed by the Australian Government. Arrangements 
should be put in place for ongoing monitoring 
of the TPP and its impacts on health, and of the 
implementation of recommendations arising from the 
formal HIA.
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Glossary
Biologic products Health technologies, such as medicines and vaccines, that are produced through biotechnological processes using living organisms
Control measure Measures (such as taxes, advertising bans and labelling requirements) used to reduce consumption of tobacco and alcohol
Co-payment A financial contribution paid by an individual towards the cost of a service
Cross-border services A chapter/set of provisions in a trade agreement relating to services provided by foreign corporations
Evergreening
Refers to the way in which the pharmaceutical industry seeks patents 
for minor modifications to existing pharmaceutical products (such as 
changes to formulations, uses and methods of delivery) in order to 
extend monopolies and delay generic competition
Expropriation The removal of private property by government
General exceptions Provisions in a trade agreement that set out circumstances in which countries may be exempted from the rules
Generic medicine
A medicine, which is a chemically identical copy of an original drug. 
Generics can be produced when the monopoly on the original product 
has expired and are generally cheaper than the original product
Health impact assessment A systematic process that determines the potential benefits and harms of a policy and offers recommendations to improve health
Healthcare transparency annex An annex to the Transparency Chapter of the TPP that sets out provisions applying to pharmaceutical pricing and reimbursement
Intellectual property rights Legal rules protecting intellectual property (such as patent and copyright laws)
Intellectual property Discoveries and creations that can be legally owned or protected
Investor-state dispute settlement 
(ISDS)
A legal process that allows corporations from one country to sue the 
government of another country for monetary compensation, outside 
of the domestic court system
Out-of-pocket Direct payments by consumers for a service
Pharmaceutical Benefits Scheme Australian Government program that subsidises prescription medicines for Australians
Precautionary principle
Refers to protective action in the absence of scientific evidence. 
In situations where there is the potential for harm, but there is 
uncertainty about the magnitude of the impact or causality, then 
only action to avoid harm or no action should be undertaken. See 
Raffensperger, C. and Tickner, J.A . Protecting public health and the 
environment: implementing the precautionary principle. Washington, 
D.C: Island Press, 1999.
Regulatory coherence
In the context of a trade agreement, provisions that aim to streamline 
regulation; specify how governments go about policy making; and 
provide for consultation and coordination mechanisms
Sanitary and phytosanitary measures Provisions in trade agreements related to imports of animal and plant related goods – such as quarantine standards
Tariff A tax applied to imported products (e.g. foodstuffs)
Technical barriers to trade
In the context of trade agreements, these refer to technical regulations 
and standards that are applied to imported products (for example, 
labelling requirements)
Therapeutic reference pricing
A pricing strategy for medicines, whereby the price of a medicine is 
linked to that of other medicines that are already available to treat the 
same condition
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Tobacco plain packaging Removal of colours, logos and other marketing materials from tobacco containers, together with placement of large graphic health warnings
Trade agreement An agreement between two or more countries that governs the flow of trade in goods and services between them
Transparency
In the context of a trade agreement, transparency provisions generally 
involve requirements to provide notice and publish information about 
policy and administrative changes, and to provide review and appeal 
mechanisms
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